Moderna (MRNA) announced that it has submitted a regulatory filing with the FDA seeking approval for an updated version of its COVID-19 vaccine Spikevax, designed to target the LP.8.1 variant of the virus.The submission is based on guidance from the FDA issued last week, which advised vaccine-makers to update their COVID-19 shots to target strains that are part of the JN.1 lineage, with a preference for the LP.8.1 variant. Per the latest CDC data, LP.8.1 currently accounts for about 70% of total cases in th ...

Core Viewpoint - Moderna's recent stock surge to approximately $27, following the FDA's recommendation for annual COVID-19 vaccinations for high-risk populations, appears to be a temporary reaction rather than a sign of a sustainable recovery, as competitors did not experience similar gains [1][2]. Financial Performance - Moderna's revenues have decreased by 38.2% year-over-year, from $6.8 billion to $3.2 billion, marking the third consecutive year of revenue decline with an average annual decrease of 45.5% over the past three years [3]. - The company reported a net loss of $3.4 billion over the last four quarters, with a net income margin of -106.9%, and operating income and cash flow margins at -118.8% and -97.2%, respectively [4]. Valuation Analysis - Moderna's price-to-sales (P/S) ratio stands at 3.2 times, appearing neutral compared to the broader market; however, this may mask deeper risks related to revenue clarity, pipeline commercialization timelines, and elevated cash burn [5]. - The stock has shown increased sensitivity during market downturns, with a 53.4% drop during the 2022 inflation surge, compared to a 25.4% decline in the S&P 500 [6]. Competitive Landscape - Compared to peers like Pfizer and Seagen, which maintain more stable revenue streams and product ranges, Moderna has faced steeper financial declines and has not adjusted guidance significantly in recent months [7]. - The absence of a similar stock rally among competitors indicates that Moderna's recent increase was not part of a broader sector trend but rather a short-term response to regulatory news [7]. Future Outlook - The recent stock surge is viewed as a temporary respite amid ongoing challenges of declining revenues and increasing losses, with the need for tangible advancements in pipeline commercialization and vaccine sales trends to ensure sustainability [8][9]. - Investors are advised to monitor revenue patterns and updates on Moderna's pipeline development closely before interpreting the recent rebound as a long-term positive trend [9].

Shares of Moderna (MRNA) declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID. Per the company, the decision was taken in consultation with the agency.This announcement did not come as a surprise since MRNA had already announced earlier this month, alongside its Q1 results, that the FDA had requested ‘Phase 3 flu efficacy data.’ This setbac ...

Moderna TodayMRNAModerna$25.80 -2.19 (-7.82%) 52-Week Range$23.15▼$170.47Price Target$53.95Add to WatchlistModerna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months. What may surprise investors is that the Moderna stock is down approximately 60% over the last five years. That means the stock has given back all the gains it made when the company’s COVID-19 vaccine ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Back in 2021, Moderna (NASDAQ: MRNA ) shares traded for around $500 per share, so it is amazing to think that at that time, even just 100 shares of this stock would have set you back by about $50,000. However, since then, it seems likeLong-time stock market investor focused on strategic buying opportunities with dividend and value stocks. This investment strategy has resulted in a near 5 star rating on Tipranks.com and over 9,000 followers on Seeking Alpha. Follow me on Twitter for my latest trading ideas: ...

Equity markets are full of bargains -- stocks that have performed terribly in recent months, whether due to trade-related marketwide issues or company-specific troubles, but could bounce back once things improve. There are also companies that are not performing well and are unlikely to rebound anytime soon; that's the kind investors should stay away from.Let's consider one stock in each category: Moderna (MRNA -1.50%), a beaten-down stock with decent prospects, and Teladoc Health (TDOC -1.02%), one whose fu ...

Moderna (MRNA) kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, the steep decline in revenues raises concerns.While sales of its COVID-19 vaccine continue to decline as expected in a post-pandemic market, Moderna is taking proactive steps to reshape its future. The company is swiftly advancing multiple pipeline candidates across late-stage development, with the intent to diversify its existing revenue base and launch multiple new products over th ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Moderna (MRNA) reported $108 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 35.3%. EPS of -$2.52 for the same period compares to -$3.07 a year ago.The reported revenue represents a surprise of -14.95% over the Zacks Consensus Estimate of $126.98 million. With the consensus EPS estimate being -$2.92, the EPS surprise was +13.70%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...